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Abstract: Fingolimod is a selective immunosuppressive agent approved worldwide for the 
treatment of relapsing-remitting multiple sclerosis (MS), a chronic and potentially disabling 
neurological condition. Randomized double-blind clinical trials have shown that fingolimod 
significantly reduces relapse rate and ameliorates a number of brain MRI measures, including 
cerebral atrophy, compared to both placebo and intramuscular interferon-β1a. The effect on dis-
ability progression remains controversial, since one Phase III trial showed a significant benefit of 
treatment while two others did not. Although fingolimod has a very convenient daily oral dosing, 
the possibility of serious cardiac, ocular, infectious, and other rare adverse events justified the 
decision of the European Medicines Agency to approve the drug as a second-line treatment for 
MS patients not responsive to first-line therapy, or those with rapidly evolving course. In the 
United States, fingolimod is instead authorized as a first-line treatment. The aim of this review 
is to describe and discuss the characteristics of fingolimod concerning its efficacy, safety, and 
tolerability in the clinical context of multiple sclerosis management.
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Introduction
Multiple sclerosis (MS) is a chronic demyelinating and degenerative disease of the 
central nervous system (CNS), characterized by recurrent episodes of neurological 
dysfunction, accumulation of irreversible disability, or both. The condition is associated 
with the pathological finding of extensive inflammation with scattered distribution in 
the CNS white matter, gray matter, and meninges, likely caused by an autoimmune 
process triggered by one or more still unidentified causal factors.1 As a consequence, 
no definitive or etiological treatment for MS exists, although several disease-modifying 
drugs (DMDs) are available that may reduce disease activity and improve the clinical 
course by modulating or suppressing the immune system. Currently approved DMDs 
in Europe, USA, and many other countries include interferon-β1a and -β1b, glatiramer 
acetate, mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, and 
alemtuzumab. Immunosuppressive drugs such as azathioprine, cyclophosphamide, 
and cladribine have a consolidated clinical use or are approved in some countries. 
After nearly two decades in which only injectable agents were approved for MS 
treatment and azathioprine was the only off-label oral option with evidence of efficacy, 
fingolimod (also known as FTY720) was the first DMD marketed as a single-daily 
capsule that showed promising therapeutic effect in MS. However, some safety issues 
were identified during the drug development process, after completion of trials, and in 
the first months of clinical use in the United States, that led to approval of fingolimod 
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as a second-line DMD by the European Medicines Agency 
(EMA) after the US Food and Drug Administration (FDA) 
had licensed it as a first-line agent. In addition, contradictory 
results regarding efficacy on progression of disability in MS 
patients were found in the two pivotal Phase III trials that 
allowed fingolimod marketing in most countries.2,3
The aim of this review is to describe and comment on the 
safety, tolerability, and clinical efficacy of fingolimod for the 
treatment of relapsing-remitting MS.
The story of an ancient  
Chinese fungus
In 1855, Miles Joseph Berckley – the founder of British 
mycology – firstly described a fungus called Cordyceps 
sinclairii in its teleomorphic form (the sexual reproductive 
stage),4 which several years later in 1923 Curtis Gates Lloyd 
classified in the genus Iseria, with its anamorphic (asexual 
reproductive stage) name, Isaria sinclairii.5 The fungus is 
endemic in southwestern China and to the alpine habitats 
of the Tibetan Plateau over 3,000 meters above sea level; it 
victimizes a particular type of cicada larvae as a host in which 
to propagate. The larvae usually die just beneath the soil 
surface, and the fungus produces white tufts, which grow up 
from the soil and release powdery white spores. Mushrooms 
species related to I. sinclairii have been used for centuries in 
Tibetan and Chinese traditional medicine as tonic, sexual-
enhancer, anticancer, and immune boosting drugs, which 
some refer to as elixir of eternal youth along with ginseng 
and deer antlers, although with poor supporting scientific 
evidence.6
In 1992, a Japanese research team headed by Dr Fujita at 
Kyoto University isolated from a culture broth of I. sinclairii 
a metabolite named ISP-1 or myriocin showing potent 
immunosuppressive properties.7 First, in vitro experiments 
showed that ISP-1 strongly inhibited the proliferation of 
T-cells in mouse allogeneic mixed lymphocyte reaction and 
significantly prolonged rat skin allograft survival; however, 
higher dose of ISP-1 induced marked toxicity in vivo. In 
1995, researchers from Yoshitomi Pharmaceuticals, after 
several processes of simplification of ISP-1, in order to 
reduce its toxicity and enhance pharmacological properties, 
synthetized 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-
diol, a new molecule abbreviated as FTY720, giving birth to 
fingolimod.8 In 1997, the Japanese company sold FTY720 
to Novartis Pharmaceuticals, which set up a development 
and research plan for fingolimod as an add-on therapy to 
cyclosporine after renal transplantation. However, after 
initial enthusiasm for the preliminary results, two large trials 
showed that fingolimod was less safe than mycophenolate 
mofetil and did not support a dose reduction of cyclosporine 
to prevent renal transplant rejection.9,10
At that stage, other studies had shown that FTY720 was 
effective in preventing experimental autoimmune encephalo-
myelitis (EAE; ie, the animal model of MS) and in decreasing 
infiltration of CD4 T-cells into the spinal cord of mice with 
EAE.11 The road for studies in MS patients was open. The 
first clinical evidence of FTY720 efficacy in MS came in 
2006 with a 6-month placebo-controlled Phase II trial, fol-
lowed by a 6-month extension in which all patients were 
switched to FTY720.12 In 2010, two major Phase III trials 
were published: the FTY720 Research Evaluating Effects 
of Daily Oral therapy in Multiple Sclerosis (FREEDOMS), 
a 24-month double-blind placebo-controlled study,2 and the 
Trial Assessing Injectable Interferon Versus FTY720 Oral in 
Relapsing-remitting Multiple Sclerosis (TRANSFORMS), 
a 12-month double-blind Phase III study comparing fin-
golimod and low-dose interferon-β1a as active treatment 
for MS.3 Both trials showed a significant benefit of fingoli-
mod on relapse rate and brain MRI outcomes, which led to 
rapid approval of the drug with the brand name of Gilenya® 
(Novartis Pharmaceuticals, Basel, Switzerland) by the FDA 
on September 22, 2010. Just a few months later, early in 
2011, the Committee for Medicinal Products for Human Use 
(CHMP) of EMA gave positive opinion for clinical use of 
Gilenya®, which in March of the same year became the first 
oral treatment officially approved for MS in all the European 
Union. In the meantime, the Cleveland Clinic 8th annual 
Innovation Summit had listed fingolimod at the 9th position 
among the top 10 medical innovations for 2011, following 
groundbreaking drugs for cancer and hepatitis C as well as 
technological innovations like florbetapir as a new molecular 
imaging biomarker for early detection of Alzheimer’s disease 
and incisionless bariatric surgery.13 During this time, the 
media also helped popularize the discovery of the new “MS 
pill.”14 But what was the buzz all about?
Clinical efficacy of fingolimod  
in multiple sclerosis
Mechanism of action
Fingolimod is a small lipophilic molecule with a sphingosine-
like structure, which exerts its biological activity after phos-
phorylation and interaction with the sphingosine-1-phosphate 
(S1P) receptor family. Fingolimod shows affinity for four of 
the five known S1P receptors subtypes, which are abundantly 
expressed on the surface of a variety of cell subtypes, 
including but not limited to endothelial cells, lymphocytes, 
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smooth muscle and cardiac myocytes, and neural cells. S1P 
receptor type 1 (S1PR1) is mainly expressed by lymphocytes 
and represents the most relevant molecular target for the 
therapeutic effect of fingolimod in MS.15 Fingolimod-phos-
phate, which is the active form of the drug, acts as a high-
affinity agonist of S1PR1 causing its downregulation on the 
cell surface and termination of the sphingosine-dependent 
intracellular signaling. S1PR1 molecular pathway is essential 
for cell migration processes, particularly of lymphocytes 
subtypes expressing the “homing” receptor CCR7, such as 
naïve and central memory T-cells, T
h
17 cells, and B-cells. 
S1PR1 internalization and loss of function induced by fin-
golimod determines an imbalance toward CCR7 signaling, 
which inhibits lymphocytes mobilization to the peripheral 
blood, leading to their segregation into secondary lymphoid 
organs. Importantly, effector memory T-cells do not express 
CCR7, and their mobilization from lymphoid tissue is not 
influenced by fingolimod, thus explaining why immunologi-
cal surveillance is substantially preserved during treatment. 
Sequestration of central memory T-cells, T
h
17 cells, and 
B-cells in the peripheral lymphoid tissue significantly reduces 
access of autoreactive lymphocytes to the CNS of patients 
with MS, thus modulating the inflammatory process that 
starts and maintains the formation of demyelinating plaques, 
axonal damage, and neuronal death. Furthermore, in vitro and 
animal models studies have shown that fingolimod interacts 
with S1PR1, S1PR3, and S1PR5 expressed by neurons, 
astrocytes, oligodendrocytes, and microglia, promoting 
several neuroprotective and regenerative events, such as 
neural stem cell migration, neuronal injury repair, increase 
of endogenous brain-derived neurotrophic factor, astrocyte 
proliferation and migration, protection of oligodendrocytes 
from cell death, increase of oligodendrocytes progenitors 
number, and remyelination.16
evidence from clinical trials
In 2003, fingolimod entered the clinical phase of the research 
pipeline for MS with the beginning of the first Phase II 
trial. The study enrolled 281 subjects with active relapsing-
remitting or secondary progressive MS who were random-
ized to receive daily fingolimod 1.25 mg, 5 mg, or placebo 
for 6 months (core phase, after which patients on placebo 
were randomized to either fingolimod dose and the entire 
cohort was followed for additional 6 months). Compared to 
patients on placebo, subjects on both fingolimod doses had 
a significantly lower number of total gadolinium-enhancing 
lesions on monthly brain MRI up to month 6, which was 
the primary outcome of the study. In addition, patients 
on fingolimod showed a benefit in a number of secondary 
outcomes, including the annualized relapse rate (ARR; 
53%–55% relative reduction compared to placebo), propor-
tion of patients free from relapses (86% fingolimod versus 
66% placebo), total cumulative number of new T2 lesions, 
and total cumulative volume of gadolinium-enhanced lesions. 
No statistically significant differences were observed between 
placebo and fingolimod groups in neurological disability 
progression and brain volume change from baseline.12 Since 
the 5 mg fingolimod dose showed no additional benefits and 
was associated with increased frequency of adverse events 
(AE) compared to the lower dose, subsequent Phase III trials 
were performed using fingolimod 1.25 and 0.5 mg doses, 
which was the dosage eventually approved for clinical use. 
FREEDOMS was the first randomized placebo-controlled 
double-blind Phase III trial involving a large number of 
relapsing-remitting MS patients (1,272 cases, of which 1,033 
completed the study) followed for 2 years.2 Subjects treated 
with both fingolimod doses showed a significantly reduced 
ARR (primary endpoint) compared to placebo, with a relative 
reduction of 54% and 60% for the 0.5 mg and the 1.25 mg 
doses, respectively. Compared to placebo, fingolimod 0.5 
mg treatment also resulted in a significantly lower risk of 
relapse (29.6% versus 54.4%), disability progression con-
firmed at 6 months (12.5% versus 19%), presence of new 
T2 lesions (49.5% versus 78.8%) and gadolinium-enhancing 
lesions (10.3% versus 34.9%) on brain MRI at 2 years. In 
addition, patients receiving fingolimod had a significantly 
reduced brain volume loss compared to placebo over the 
whole study period. Data from the FREEDOMS trial were 
further analyzed in a major post hoc study with the objec-
tive of identifying potential patient subgroups with distinct 
treatment response profile.17 Overall analysis revealed that 
ARR reduction was consistently observed in all demographic, 
clinical, and MRI subgroups, with the exception of subjects 
over 40 years of age who had no significant ARR decrease 
over 2 years of fingolimod treatment compared to placebo. 
In addition, patients of female sex, previously treated with 
other DMDs, with less than 3 relapses in 2 years before 
study, with baseline expanded disability status scale (EDSS) 
score ,4.0, or with T2 lesion volume #3,300 mm3 on 
baseline brain MRI did not have a significant benefit on the 
risk of disability progression at 2 years while on fingolimod 
compared to placebo.
TRANSFORMS was a contemporary – although shorter 
than FREEDOMS – double-blind randomized Phase III trial 
comparing the efficacy and safety of two fingolimod doses 
and intramuscular interferon-β1a 30 µg once a week in 
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1,292 relapsing-remitting MS patients followed for 1 year 
(89% of cases completed the study).3 Fingolimod treatment 
resulted in an ARR relative reduction up to 51% compared to 
interferon (0.20 for fingolimod 1.25 mg, 0.16 for fingolimod 
0.5 mg, and 0.33 for interferon; P,0.001 for both fingolimod 
doses versus interferon) independent of previous use of other 
DMDs. Nearly 83% of patients on fingolimod 0.5 mg/day 
remained relapse free during the trial versus 69% of patients 
on interferon. Overall, neurological disability progression 
occurred at a very low rate (less than 8% in 1 year) in the 
study population and no statistically significant differences 
were evident between fingolimod and interferon in terms of 
EDSS score worsening confirmed at 3 months. However, 
the 1-year change on the EDSS and Multiple Sclerosis 
Functional Composite (MSFC) favored fingolimod over 
interferon, although the clinical relevance of such difference 
is uncertain. MRI data analysis revealed that fingolimod 
treatment had a better outcome compared to interferon on 
several measures, including the number of new or enlarged 
brain lesions on T2-weighted images, number of gadolinium-
enhancing lesions on T1-weighted images, and the change 
from baseline in brain volume. However, the change from 
baseline in volume of T2-hyperintense and T1-hypointense 
lesions – which are considered expression of MS inflam-
matory burden and axonal loss, respectively – did not differ 
significantly between fingolimod and interferon groups. 
A post hoc analysis of TRANSFORMS published 3 years 
later revealed that the benefit of fingolimod over interferon 
on relapse rate reduction was confirmed in several subgroups 
with the exception of male patients, subjects over 40 years 
of age, and patients with baseline EDSS score .3.5.18 In the 
latter category also, the number of gadolinium-enhancing 
and new T2 lesions on brain MRI at 1 year did not differ 
significantly between fingolimod and interferon, while brain 
volume change remained in favor of fingolimod.
More recently, FREEDOMS II, a third Phase III trial 
of fingolimod, was conducted predominantly in USA and 
Canada. This was a double-blind randomized placebo-
controlled 2-year study that included over 1,000 relapsing-
remitting MS patients, with a dropout rate of 28%.19 Starting 
from November 2010 after fingolimod approval by the FDA, 
the study continued open-label to allow patients on placebo 
to switch to fingolimod. The trial replicated the findings 
of FREEDOMS regarding the ARR and MRI outcomes. 
However, the significant effect on reducing EDSS score 
progression observed in FREEDOMS was not confirmed 
in the FREEDOMS II trial, although it has to be noted that 
confirmed disability worsening occurred in a relatively low 
proportion of cases in both fingolimod and placebo groups 
(13.8% and 17.8% at 2 years, respectively). On the other 
hand, disability as measured by MSFC showed a statistically 
significant change in favor of fingolimod treatment. In 
addition to “hard” outcome measures, FREEDOMS II 
included evaluation of patient-reported outcomes and symp-
toms using the Euro quality of life scale, Patient Reported 
Indices in Multiple Sclerosis, and Modified Fatigue Impact 
Scale. The scores obtained by patients in these question-
naires did not significantly differ between fingolimod and 
placebo groups.
Finally, the recently completed INFORMS trial showed 
no significant benefit of fingolimod on neurological disability 
in primary progressive MS patients treated for at least 
3 years.20
Observational studies
Extension studies conducted after the conclusion of random-
ized double-blind trials showed substantial clinical and MRI 
stability of MS patients continuing to receive fingolimod 
and overall amelioration of MS activity measures in patients 
switching from placebo or intramuscular interferon to 
fingolimod.21–23 However, this type of study is not designed 
to assess efficacy of a therapeutic intervention, and any 
conclusion in this regard based on observational open-label 
data should be avoided.
In the last 3 years, clinicians have devoted much attention 
to the matter of comparative efficacy of fingolimod versus 
other DMDs, particularly natalizumab that is the major 
“competitor” in terms of indications and clinical use profile 
in MS. There are no randomized trials directly comparing 
natalizumab and fingolimod efficacy. The only available data 
derive from case series and observational studies, either on 
MS patients who shifted from natalizumab to fingolimod, 
generally but not always showing a disease reactivation after 
the switch,24–31 or on active MS cases despite first-line disease-
modifying treatment who were switched to fingolimod or 
natalizumab as second-line option, suggesting a possible 
superior efficacy of natalizumab on relapse rate and progres-
sion of disability.32–34 One single retrospective study reported 
analogous efficacy of the two drugs.35 Interestingly, it has 
been suggested that early fingolimod start after natalizumab 
cessation (ie, no later than the recommended natalizumab 
3-month washout interval) reduces relapse risk compared 
to longer treatment discontinuation.36–41 This strategy has 
proved also effective on MRI outcomes in a recent random-
ized trial comparing different natalizumab washout intervals 
before switching to fingolimod,42 suggesting that timing of 
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DMD change may be crucial in MS patients with a history of 
active disease. Notably, it has been reported that fingolimod 
withdrawal can also lead to rebound of MS activity, possibly 
with severe clinical and MRI features.43–47
Fingolimod safety and tolerability
Aes in clinical trials
Pooled analysis of long-term safety data from Phase II/III 
studies showed that fingolimod 0.5 mg resulted in transient 
and rarely symptomatic (0.5%) bradycardia and second-de-
gree atrioventricular block on treatment initiation, minor blood 
pressure increase, frequent (9%) but generally asymptomatic 
liver enzyme elevations, mild blood cholesterol level increase, 
and macular edema (ME; 0.4%). In addition, fingolimod-
treated subjects had a mild decrease of forced expiratory 
volume in the first second, which was not associated with any 
clinically relevant event. In fact, the reduction in peripheral 
blood lymphocyte count induced by the drug was the most 
commonly observed undesired effect, although only a total 
lymphocyte count below 200 cells/mm3 was considered an 
AE as per protocol. Overall, infection rates and malignancy 
numbers were comparable between treatment groups. The 
incidence of serious AEs and treatment discontinuations due 
to AEs was similar with fingolimod 0.5 mg and placebo.48
Cardiovascular Aes
Pooled analysis of the first dose monitoring data from pivotal 
Phase III trials revealed that fingolimod induced a transient 
reduction in heart rate and atrioventricular conduction, 
resulting in symptomatic bradycardia or second-degree atrio-
ventricular block in only 0.6% and 0.2% of patients taking 
the 0.5 mg dose, respectively.49 An Italian open study on the 
safety and tolerability of fingolimod first dose in a large group 
of 906 patients showed that most (95.2%) did not experience 
any AE after fingolimod administration.50 Cardiovascular AEs 
occurred in 18 patients and included bradycardia (1.3%), first- 
and second-degree atrioventricular block (0.1% and 0.2%, 
respectively), palpitations, sinus arrhythmia, and ventricular 
premature beats (0.1% each). No event required medical 
intervention, being self-limited. Extended cardiac monitoring 
beyond 6 hours was required in less than 5% of patients. 
Similar results were reported in a Phase IIIb multicenter study 
as well as in the postmarketing experience.51–53
infections
Two fatal cases of infection – one disseminated varicella-
zoster virus (VZV) infection and one herpes simplex virus 
(HSV) encephalitis – were reported in the TRANSFORMS 
among MS patients receiving the higher fingolimod dose.3 
Overall, an increased incidence of VZV infections in fingoli-
mod versus placebo-treated patients was observed in pooled 
data from six Phase II and III trials and their extensions 
for about 11,915 patient-years of fingolimod treatment.54 
In fingolimod-treated patients the incidence of VZV infec-
tions was nearly twice that in controls (11 versus 6 per 
1,000 patient-years) and included 149 cases: 125 (84%) with 
uncomplicated herpes zoster (HZ) involving 2 contiguous 
dermatomes or less, 10 (7%) ophthalmic HZ, 2 cases of 
disseminated HZ (1%) and 11 cases involving bilateral HZ 
or HZ in more than 2 contiguous dermatomes (7%). The 
biological reason underlying the increased frequency of VZV 
infections in patients taking fingolimod is probably correlated 
with its effects on CD8 T-cell’s effectors functions.
Macular edema
ME with or without visual symptoms has been reported in 
0.5% of patients exposed to fingolimod in FREEDOMS and 
TRANSFORMS trials, occurring predominantly in the first 
3–4 months of therapy.55 The condition is caused by fluid 
accumulation in the central retina or macula and symptoms 
include decreased acuity and metamorphopsia, although ME 
is frequently asymptomatic. ME detection is based on fundus 
oculi examination, retinal optical coherence tomography, and 
intravenous fluorescein angiography if needed. An ophthal-
mological evaluation is recommended at 3–4 months after 
treatment initiation and at regular intervals thereafter.56 The 
risk of fingolimod-associated ME is increased in patients 
with diabetes mellitus or uveitis, and most cases of ME in 
the trials occurred in patients older than age 41. The mecha-
nism of ME development is likely related to effects of S1P 
pathway activation on vascular permeability. Fingolimod-
related ME tends to resolve spontaneously after treatment 
discontinuation.
Postmarketing reported Aes
As of November 2014, approximately 112,000 patients were 
treated with fingolimod worldwide, and there were 195,000 
patient-years of drug exposure in both clinical trials and the 
postmarketing,57 which is the ideal setting to monitor and 
recognize the occurrence of therapy AEs.
Sudden death
In November 2011, a report of the sudden death in a hyperten-
sive patient on calcium-channel blockers and β-blockers less 
than 24 hours following first-dose fingolimod prompted the 
FDA and EMA to review safety data on Gilenya®. FDA could 
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not conclude that fingolimod was related to unexplained 
death, but it remained concerned about the cardiovascular 
effects of the drug after the first dose.58 In January 2012, 
CHMP assessed the reports of 15 cases of sudden or unex-
plained death in patients treated with Gilenya®.59 Most of the 
deaths and cardiovascular events had occurred in patients 
with a history of cardiovascular problems or in those taking 
other medicines. However, the data were not conclusive as 
to whether Gilenya® was the cause of the death. Both FDA 
and EMA recommended changes to the product informa-
tion to strengthen the existing warnings and ensure close 
monitoring of all patients, advising doctors to perform 
electrocardiogram monitoring for 6 hours after taking the 
first dose, to consider the need for extended monitoring, as 
well as to exclude patients on medications that can cause 
cardiac rhythm abnormalities. With these risk-minimization 
measures in place, both FDA and EMA conclusions were that 
the benefits of Gilenya® outweigh the risks. A recent Italian 
study on 53 MS patients starting fingolimod showed that the 
exposure to the drug significantly reduced left ventricular 
systolic function at 6 months, compared to natalizumab, 
which did not induce any significant change in a control 
group of 25 MS subjects.60
Progressive multifocal leukoencephalopathy
Progressive multifocal leukoencephalopathy (PML) is a 
rare, severe, and potentially fatal brain infection caused by 
the John Cunningham virus (JCV), a common virus that is 
harmless in most people but can cause PML in patients with 
immunodeficiency or in those taking immunosuppressive 
drugs. In August 2013, FDA announced the first case of a 
patient developing PML while treated with Gilenya®, and 
after that an additional case was reported. The two PML cases 
could not be conclusively linked to fingolimod because prior 
to this drug the patients had been treated with natalizumab, 
a known cause of PML.61,62
In August 2015, Novartis notified the FDA that one 
more patient developed definite PML and one had probable 
PML while taking fingolimod. Neither patient had prior 
exposure to natalizumab or other immunosuppressants for 
MS or any other medical condition. Gilenya® was stopped 
in both patients.63 The probable PML case was that of a 
49-year-old patient with a 5-year history of MS previously 
treated with Rebif® (interferon-β1a from Merck Biopharma, 
Darmstadt, Germany) for 10 months and then with Gilenya®, 
in addition to short-term corticosteroids before and during 
fingolimod treatment, for approximately 4 years. On a rou-
tine brain MRI, new lesions considered atypical for MS and 
compatible with PML were detected. A cerebrospinal fluid 
(CSF) sample taken at that time was positive for JCV DNA, 
and the diagnosis of probable PML was consistent with 
diagnostic criteria outlined in the American Academy of 
Neurology consensus statement64 in the absence of clinical 
signs or symptoms specific of PML. The definite PML case 
was a 54-year-old patient who developed PML after taking 
Gilenya® for approximately 2.5 years. The patient had a 
14-year history of MS and had previously been treated 
with interferon-β1b for approximately 11 years and with 
mesalazine for ulcerative colitis for the last 4 years. The 
patient also had a history of colorectal cancer treated with 
chemotherapy and radiation treatment in the past. The patient 
was hospitalized with suspected PML after developing new 
symptoms, including walking instability, clumsiness, inatten-
tion, somnolence, and mental sluggishness. Subsequently, the 
diagnosis of PML in this patient was established on the basis 
of symptoms, characteristic MRI findings, and the detection 
of JCV DNA in the CSF.
Other viral infections
A study evaluating postmarketing data referring to about 
54,000 patient-years of fingolimod use found a reported rate 
of HZ lower than that of clinical trials (7 per 1,000 patient-
years).54 However, as a shrewd editorial from Tyler65 noted, 
lower rates of AEs occurring in postmarketing studies may 
result from incomplete data capture or several issues related 
to the FDA Adverse Events Reporting System (FAERS) (vol-
untary basis, variable diagnostic accuracy, publicity bias, etc). 
Among the recommendations for risk mitigation in patients 
initiating a therapy with fingolimod, one has to consider two 
doses of the live-attenuated VZV vaccine 4 weeks apart in 
those individuals without serologic evidence of immunity to 
the virus 1 month before starting fingolimod. If complicated 
HZV infection develops in a patient receiving fingolimod, 
treatment should be discontinued and the case promptly 
treated with intravenous acyclovir (10 mg/kg 3 times daily 
for 7–10 days), while cases with uncomplicated disease can 
likely remain on fingolimod and be treated with oral formu-
lations of acyclovir.54
Cases of severe HSV encephalitis and of VZV encepha-
litis in an immunized patient have also been reported in the 
postmarketing.66,67
Rare Aes
A variety of rare AEs associated with fingolimod treatment 
have been reported as single case reports or small case 
series including but not limited to posterior reversible 
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encephalopathy syndrome,68 cryptococcal meningoencephalitis 
and disseminated cryptococcosis,69,70 Kaposi sarcoma,71 
tumefactive demyelination,72–74 severe autoimmune hemolytic 
anemia,75 asthma deterioration,76 amenorrhea,77 peripheral 
vascular adverse effects,78 ecchymotic angioedema-like 
cutaneous lesions,79 reversible cerebral vasoconstriction 
syndrome,80 lymphomatoid papulosis,81 and hemophagocytic 
syndrome (this rare disorder due to cytokine dysregulation 
has been reported in association to infection in two patients 
treated with fingolimod for 9 and 15 months, respectively, 
both with fatal outcome).82,83
Pregnancy outcomes
The assessment of pregnancy outcomes from Phase II, III, 
and IV clinical studies showed that of the 66 pregnancies 
during which in utero exposure to fingolimod occurred, 
24 were electively terminated, and five were either lost to 
follow up or were ongoing. Three-quarters of the remaining 
37 pregnancies resulted in live births, while nine resulted 
in spontaneous abortion. In total, five cases (7.5%) of 
abnormal fetal development were recorded: in all these 
cases, fetal exposure to the drug took place in the first 
trimester of pregnancy.84 Given the risks of teratogenicity, 
women of childbearing potential should use effective con-
traception during fingolimod therapy and for 2 months after 
discontinuation.85 A fingolimod pregnancy registry has been 
established to record data on pregnancy outcomes.
Tolerability
Most patients tolerate fingolimod well at a once-a-day dosing 
oral therapy. Side effects often reported are fatigue, headache, 
malaise, back pain, and gastrointestinal discomfort, which 
however are persisting or lead to treatment discontinua-
tion within 1–2 years only in a minority of cases (around 
10%–15%), according to both clinical trials findings and 
observational studies.2,3,19,86 In the recent EPOC study, patient 
satisfaction and quality of life with fingolimod appeared to be 
better than with first-line injectable DMDs (ie, interferon-β 
and glatiramer acetate), although the most commonly 
reported AEs were more frequent in patients who switched to 
fingolimod than in those who remained on injectable DMDs 
(headache: 12% versus 3%; fatigue: 12% versus 6%).87
Discussion
When fingolimod entered clinical use in 2010, it added to the 
preexisting therapeutic options for MS as an innovative oral 
DMD capable of strongly reducing inflammatory activity of 
the disease and with a promise for potential neuroprotection, as 
indicated by the novel mechanism of action and the results of 
both preclinical and clinical studies. In fact, data from pivotal 
trials – FREEDOMS, TRANSFORMS, and FREEDOMS II – 
consistently showed that fingolimod significantly reduces 
the relapse rate, suppresses inflammatory activity on brain 
MRI, and slows brain atrophy progression in MS patients 
compared to placebo and intramuscular interferon.2,3,19 
However, a reduction in neurological disability worsening 
was observed only in FREEDOMS, suggesting a potential 
heterogeneity of biological and clinical characteristics of MS 
populations across trials and also indicating the need for cau-
tion when interpreting the presence of a beneficial effect on 
brain atrophy that is dissociated from the effect on disability 
progression in MS. This is a well-known phenomenon in the 
history of MS DMDs trials, which could be explained by the 
fact that slowing of brain atrophy over 1–2 years may have 
marginal clinical impact in the short term of disease course, 
although a pooled analysis of data from 13 randomized 
controlled trials of various DMDs including .13,500 MS 
patients revealed a significant correlation between the effect 
on brain atrophy and the effect on disability progression over 
2 years.88 Other possible explanations exist that are beyond 
the scope of this review.89
Unfortunately, no head-to-head randomized double-blind 
trials have been done to compare fingolimod to other estab-
lished first- or second-line DMDs that are known to be more 
effective than intramuscular interferon once a week, such as 
subcutaneous interferon three times a week, mitoxantrone, or 
natalizumab.90 Nevertheless, with the limitations of indirect 
comparisons, it can be stated that the ARR reduction obtained 
with fingolimod versus placebo at 2 years (around 50%), 
is greater than that observed with interferons, glatiramer 
acetate, or teriflunomide (around 30%) and similar to that 
reported with dimethyl fumarate, among first-line DMDs, 
which share the same lacking or conflicting evidence for dis-
ability progression.91 Fingolimod trials have shown a lower 
ARR reduction compared to second-line therapies, such as 
natalizumab (-68% versus placebo), mitoxantrone (-65% 
versus placebo), and the newly approved monoclonal anti-
body alemtuzumab (up to -55% versus high dose interferon-
β1a), as confirmed by a recent network meta-analysis.92 In 
addition, natalizumab, mitoxantrone, and alemtuzumab 
treatment are associated with a significant, although modest, 
reduction of disability progression risk, with the exception 
of the CARE-MS I trial in which the difference between 
alemtuzumab and interferon three times a week was not 
significant. In terms of MRI outcomes, fingolimod has an 
efficacy profile concerning inflammatory activity measures 
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that is closer to first-line than second-line therapies, while 
it shows the more robust and consistent benefit on brain 
atrophy than all other DMDs. Fingolimod appears as an ideal 
second-line DMD for MS patients who are also eligible for 
natalizumab but test positive for serum anti-JCV antibodies 
(around 50% of population) and are therefore at increased 
risk of PML during natalizumab treatment.
In 2010, FDA approved fingolimod for relapsing-remitting 
MS with or without previous use of interferon-β, while in 
2011 EMA authorized the use of fingolimod as second-line 
treatment for relapsing-remitting MS with either high  disease 
activity despite interferon treatment (extended to any other 
DMD in 2014) or untreated rapidly evolving severe disease 
as defined by clinical and MRI activity criteria. In 2012, the 
National Institute for health and Care Excellence recom-
mended the use of the drug in the United Kingdom with an 
indication similar to that issued by EMA. One of the critical 
factors that led to fingolimod approval as a second-line DMD 
stood in safety data of Phase II and III trials, reinforced by 
postmarketing reports issued after Gilenya® marketing in 
USA as described in the “Fingolimod safety and tolerability” 
section of this review. Although fingolimod launch as the 
first new-generation “pill” for the treatment of MS stressed 
the advantage of an easy-to-use daily oral therapy, safety 
concerns were evident since the first trials and still remain to 
be vigilantly considered in each patient who is prescribed this 
drug. Potentially serious or even lethal adverse events, such 
as cardiovascular, hepatic, and infectious complications, may 
be prevented or identified in time by strict monitoring of the 
first dose and continuing to do so regularly during treatment 
period. However, an even more important step in assuring 
patient safety is the identification of comorbidities and other 
factors that predispose to certain types of adverse events 
prior to fingolimod initiation to minimize the risks versus 
the potential benefits. Fingolimod is contraindicated in MS 
cases with clinically relevant heart disease, infection, cancer, 
immunodeficiency, severe liver disease, uncontrolled hyper-
tension, diabetes, lung disease, retinal conditions or a history 
of uveitis. Treatment with β-blockers and calcium channel 
blockers increases the risk of fingolimod-associated cardiac 
AEs, and so concomitant use of these drugs should be avoided. 
Simultaneous administration of other immunosuppressive or 
immunomodulatory therapies and long-standing steroid treat-
ment are contraindicated because they may increase the risk of 
infections; short-term high-dose intravenous steroids typically 
used for MS relapses are allowed, although they must be pre-
scribed with caution since some infectious serious AEs have 
been reported after exposure to high-dose methylprednisolone 
in patients receiving fingolimod.3 Finally, in case of diagnostic 
uncertainty, extreme caution has to be used before prescribing 
fingolimod since it could worsen certain MS-like conditions, 
such as neuromyelitis optica.93
Conclusion
Fingolimod is an effective oral treatment for reducing relapse 
rate, brain MRI inflammation, and brain atrophy in patients 
with relapsing-remitting MS naïve to treatment or previously 
treated with a first-line DMD. Fingolimod efficacy in pre-
venting disability progression – as measured by EDSS score 
worsening – is uncertain in the short-term (1–2 years) and 
unknown in the medium long term (3 years or more), although 
the robust and consistent beneficial effect observed on brain 
atrophy may indicate a possible neuroprotective effect that is 
not captured by an empirical tool as the EDSS. Fingolimod 
tolerability is generally good or excellent. However, serious 
adverse events such as cardiac arrhythmias, macular edema, 
viral infections, severe lymphopenia, and other rare condi-
tions may occur. For this reason, fingolimod appears a valid 
option for the treatment of patients with active relapsing-
remitting MS, after careful evaluation of concomitant 
conditions and medication and assuring adequate first-dose 
and long-term monitoring, as pointed out by the recently 
revised EMA report on Gilenya®.94 Head-to-head clinical 
trials against natalizumab and other newer DMDs as well 
as observational studies to assess fingolimod safety in the 
long-term are warranted.
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